Drug · DIN 02216167
IMOVANE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since May 24, 2022; first marketed February 10, 1998.
- Drug Identification Number (DIN)
- 02216167
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Zopiclone N05CF01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ZOPICLONE | 5.0 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 18, 2006: NOC 7886New Drug Submission (NDS) · Manufacturer name change
- October 5, 2000: NOC 1497New Drug Submission (NDS)
- December 23, 1996: NOC 4742Supplement to a New Drug Submission (SNDS) · New strength
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “imovane”. A notice may cover another product or only some lots: read it to see what it covers.
- IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For Health ProfessionalsNovember 19, 2014 · Drugs · Product safety
- IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the PublicNovember 19, 2014 · Drugs · Product safety
Other DINs named IMOVANE
- DIN 01926799 · Marketed